Moderna, Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? Moderna, Inc. trades at $135.86 (market cap $56.02B), while Roundhill NVDA WeeklyPay ETF trades at $37.12. The key difference: Moderna, Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | NVDW | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $174.38 | $52.33 |
52-Week Low | $22.36 | $31.88 |
Enterprise Value | $52.17B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
NVDW (Roundhill NVDA WeeklyPay ETF) trades at $37.60, down 3.22% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to Nvidia with weekly dividend payments, though key valuation ratios remain unavailable. Recent news highlights its high-yield income strategy tied to NVDA's performance, with payouts fluctuating based on underlying stock volatility.
The outlook depends heavily on Nvidia's continued earnings strength and AI market momentum. Key risks include leverage amplification during NVDA downturns and variable dividend sustainability. Investors seeking weekly income from tech exposure may find value, but must monitor NAV erosion risks amid sector volatility.
Trailing returns across standard periods
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →